Sarver Heart Center Grand Rounds - Guest Speaker Series

Touchscreen Summary: 

Speaker:  Walter Koch, PhD from the Lewis Katz School of Medicine, Temple University in Philadelphia

W.W. Smith Chair in Cardiovascular Medicine
Professor and Chair, Department of Pharmacology
Director, Center for Translational Medicine

Topic: Targeting GRK2 in Heart Failure

Event Series: 
Cardiology Grand Rounds
March 10, 2017 - 12:00pm - 1:00pm
Event Location: 
Sarver Heart Center Room 4137

Walter J. Koch, PhD, is the inaugural holder of the W.W. Smith Chair in Cardiovascular Medicine at the Lewis Katz School of Medicine at Temple University. He is the chairperson of the Department of Pharmacology and director of the Center for Translational Medicine.

Dr. Koch started his career at the University of Cincinnati College of Medicine where he received his PhD in Pharmacology and Cell Biophysics in 1990 under the mentorship of Dr. Arnold Schwartz. He then went to Duke University Medical Center and the Howard Hughes Medical Institute as a postdoctoral fellow (1990-1995) in the lab of Dr. Robert Lefkowitz (Nobel Prize in Chemistry, 2012). He was recruited to start a molecular cardiovascular biology laboratory in the Department of Surgery at Duke in 1995 and advanced to tenured full professor in 2001. In 2003 he was recruited to lead the newly established Center for Translational Medicine at Thomas Jefferson University and successfully built that center before moving it to Temple in 2012.

The Koch lab studies molecular mechanisms for cardiac injury and repair focusing on G protein-coupled signaling in the heart and development of novel molecular strategies to repair the heart, including gene therapy and stem cell mediated regeneration. His research work has revealed the novel roles G protein-coupled receptor kinases (GRKs) play in cardiac injury and repair. Manipulating these GRKs, and targeting them with therapeutics, could lead to new treatments for heart failure patients. In fact, inhibition of one GRK, GRK2, in the heart has led to the reversal of heart failure. This has been shown to occur by using a gene therapy approach in pre-clinical studies in both small and larger animal models and this methodology is one step away from human clinical trials. Dr. Koch heads a large laboratory group that is well funded and has trained over five fellows in the last 20 years.

Numerous awards and honors have recognized Dr. Koch’s research over recent years including the International Society for Heart Research 2011 Outstanding Investigator Award, the Jefferson Medical College Inaugural Career Achievement Award in Biomedical Sciences in 2010, the American Heart Association Thomas Smith Memorial Lecture and Award for Cardiovascular Signaling in 2009, and the 10-year MERIT award running through 2019. Dr. Koch naturally is quite active within his field as he has chaired NIH and AHA study sections and he has been chair of BCVS at AHA and is currently the chair of the AHA’s Council Operations Committee.  He also is an Associate Editor of Circulation Research.